Controversial Vaccine Trial in Guinea-Bissau Receives Approval to Proceed

A controversial medical research trial involving newborns in Guinea-Bissau has received official approval to move forward. The project, which was previously suspended due to international outcry, will study the effects of delaying the hepatitis B vaccine for infants. Under the plan, researchers intend to enroll 14,000 babies, giving the vaccine to half of them at birth while withholding it from the others for the first six weeks of life.

According to The Guardian, the ethics committee at the University of Southern Denmark voted this week to allow the trial to proceed. Officials in Guinea-Bissau have also given their support to the project. This decision comes after the country’s health minister, Quinhin Nantote, had previously announced that the study was suspended earlier this year. The approval of the new study protocol marks a significant turn in a project that has faced intense scrutiny from the global medical community.

The trial is a central part of the vaccine vision for Robert F. Kennedy Jr., who serves as the secretary of the US Department of Health and Human Services. Kennedy has long expressed skepticism about vaccines and has promoted the idea of reducing the use of birth-dose vaccinations. Paul Offit, an infectious disease physician at the Children’s Hospital of Philadelphia, told The Guardian that Kennedy would not be able to conduct this trial in the United States because of its serious ethical concerns. Offit questioned whether the researchers are taking advantage of a developing country, noting that the study essentially treats some children as more expendable than others.

Ars Technica reports that the US Centers for Disease Control and Prevention (CDC) has set aside $1.6 million in its budget for the project. This funding is expected to be matched by private organizations, including the Pershing Square Foundation and the Bluebell Foundation. The decision to use public funds for this trial has caused anger among health experts, especially because the money could have been used for other urgent global health needs, such as fighting the Ebola outbreak in the Democratic Republic of the Congo.

The research is led by Danish scientists Christine Stabell Benn and Peter Aaby. According to Ars Technica, the pair is currently under investigation by Danish authorities regarding allegations of scientific misconduct and falsification in their previous work. The trial’s design has also led to internal conflict within the oversight committee. Stig Børsen Hansen, a founding member of the review group, resigned in protest on Friday. He described the trial as a "lottery" for newborns, noting that children who are randomly chosen not to receive the vaccine face the risk of contracting a virus that can cause lifelong damage, such as liver cancer or liver cirrhosis.

In response to the growing criticism, the researchers have updated their study protocol. According to details shared with The Guardian, the team will now test mothers for hepatitis B before they give birth. If a mother tests positive, her baby will receive the vaccine and will not be part of the trial. However, babies born to mothers who test negative may still be enrolled in the study. Critics argue that this does not solve the fundamental problem, as infants can still be exposed to the virus through community contact after birth.

As of now, the CDC, the Danish research team, and the government of Guinea-Bissau have not provided further comments to the media regarding the specific concerns raised by experts. The situation remains a point of deep division in the public health world. While the researchers maintain that their study is important for testing their hypothesis, many doctors and ethicists continue to warn that the risks to the children involved are simply too high to justify the project. With the trial now moving toward the implementation phase, the international community continues to watch the situation closely to see how the researchers will address these ongoing ethical challenges.